Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AAPG vs UK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UK Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–5 Matrix Metrics)

UK Overall Winner 6-Pillar Tally: AAPG 2 – 2 UK (2 Tie) Matrix Metrics: AAPG 5 – 5 UK

As of Nov 20, 2026, Ucommune International Ltd (UK) is the stronger overall head-to-head candidate over Ascentage Pharma Group International American Depository Shares (AAPG) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). AAPG carries a Unified Composite Score of 37.1/100 (SELL) at $11.97 (8.4x Forward P/E, -219.5% operating margin), whereas UK carries 41.3/100 (SELL) at $1.10 (N/M Forward P/E, -146.0% operating margin).

  • Growth vs. Quality Trade-Off: UK earns the overall head-to-head edge with a stronger Unified Composite Score (41.3/100 SELL vs. AAPG 37.1/100 SELL) and 7.12β · 83% Vol risk profile, whereas AAPG leads top-line expansion (+29.3% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although UK compares more favorably head-to-head, both AAPG (37.1/100 SELL) and UK (41.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: AAPG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.8); meanwhile UK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AAPG vs UK
AAPG NASDAQ
Ascentage Pharma Group International American Depository Shares
Pharmaceutical Preparations
$11.97
-3.78% 1D
Market Cap $1.2B
TTM Revenue $643M
Forward P/E 8.4x
Beta / 30D Vol 1.36β · 64% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 29
RSI-14: 28.8 · SMA20: $14.33 · SMA50: $14.97
UK NASDAQ Head-to-Head Winner
Ucommune International Ltd Ordinary Shares
Services-Business Services, Nec
$1.10
-9.84% 1D
Market Cap $827,100
TTM Revenue $26M
Forward P/E N/M
Beta / 30D Vol 7.12β · 83% Vol
Unified Composite Score
41.3 / 100 SELL
Tech 25.0 Fund 51.0 Flow 50.0 Mom 65.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.8%), weak momentum, RSI 23
RSI-14: 22.9 · SMA20: $1.56 · SMA50: $1.79

6-Pillar Scorecard Institutional Category Breakdown (AAPG 2 – 2 UK)

Columns: Metric · AAPG · UK
1. Valuation Multiples AAPG
Forward P/E 8.4x N/M
Trailing P/E 8.4x N/M
PEG Ratio N/M N/M
EV / Revenue 1.8x N/M
2. Growth & Scale AAPG
Revenue Growth (YoY) +29.3% -45.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $643M $26M
Market Cap $1.2B $827,100
3. Profitability & Quality UK
Gross Margin 93.9% -2.9%
Operating Margin -219.5% -146.0%
Net Profit Margin -228.5% -144.9%
Return on Equity (ROE) -236.6% -26.1%
4. Balance Sheet & Cash Flow UK
Cash Generation (TTM) -$1.34B EBITDA -$35M EBITDA
Cash Flow Margin N/A -133.6% EBITDA Mgn
Net Cash / Leverage $0.89 Book/Sh · -236.6% ROE $42.15 Book/Sh · -26.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Real Estate Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AAPG (5) vs UK (5)
Institutional Metric AAPG UK Criterion Row Edge
Market Capitalization
Scale
$1.2B $827,100 Larger Scale AAPG
Trailing P/E Ratio
Valuation
8.4x N/M Lower Multiple AAPG
Forward P/E Ratio
Valuation
8.4x N/M Lower Multiple AAPG
Revenue Growth (YoY)
Growth
+29.3% -45.4% Higher Growth AAPG
Operating Margin (TTM)
Profitability
-219.5% -146.0% Higher Margin UK
Net Profit Margin
Profitability
-228.5% -144.9% Higher Margin UK
Return on Equity (ROE)
Capital Efficiency
-236.6% -26.1% Higher ROE UK
52-Week Range Position
Momentum
0% ($12–$34) 15% ($0–$6) Stronger Trend UK
Beta / 30D Volatility
Risk Regime
1.36β · 64% Vol 7.12β · 83% Vol Lower Realized Risk AAPG
Unified Institutional Score
Composite Signal
37.1 / 100 (SELL) 41.3 / 100 (SELL) Higher Composite UK
Trailing 12M Revenue (USD)
Operating Scale
$643M $26M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
93.9% -2.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.8x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.34B EBITDA ($0.89 Book/Sh · -236.6% ROE) -$35M EBITDA ($42.15 Book/Sh · -26.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AAPG +19.46 pp
AAPG: -19.77% · UK: -39.23%
3M Horizon AAPG +19.0 pp
AAPG: -28.37% · UK: -47.37%
6M Horizon AAPG +26.78 pp
AAPG: -39.48% · UK: -66.26%
1Y Horizon UK +72.59 pp
AAPG: -62.59% · UK: +10.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AAPG vs UK. Trailing 12-month operating profitability (AAPG -219.5% vs UK -146.0%) and valuation multiples (AAPG 8.4x vs UK N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AAPG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$643M
Gross Margin93.9%
Op. Margin-219.5%
ROE / Fwd P/E-236.6% · 8.4x
UK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$26M
Gross Margin-2.9%
Op. Margin-146.0%
ROE / Fwd P/E-26.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AAPG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AAPG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
UK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AAPG Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and -219.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
UK Moat Profile Cyclical / Execution-Driven Positioning
Real Estate Services Operator
Competes within the Real Estate Services value chain with $827,100 market capitalization and -146.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AAPG vs UK Key Questions & Quantitative Answers

As of Nov 20, 2026, Ucommune International Ltd (UK) is the stronger overall head-to-head candidate over Ascentage Pharma Group International American Depository Shares (AAPG) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). AAPG carries a Unified Composite Score of 37.1/100 (SELL) at $11.97 (8.4x Forward P/E, -219.5% operating margin), whereas UK carries 41.3/100 (SELL) at $1.10 (N/M Forward P/E, -146.0% operating margin). Growth vs. Quality Trade-Off: UK earns the overall head-to-head edge with a stronger Unified Composite Score (41.3/100 SELL vs. AAPG 37.1/100 SELL) and 7.12β · 83% Vol risk profile, whereas AAPG leads top-line expansion (+29.3% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although UK compares more favorably head-to-head, both AAPG (37.1/100 SELL) and UK (41.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: AAPG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.8); meanwhile UK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AAPG leads the Growth & Scale pillar: AAPG posts +29.3% YoY revenue growth and +0.0% YoY earnings growth on $643M TTM revenue (93.9% gross margin, -219.5% operating margin), compared with UK at -45.4% YoY revenue growth and +0.0% YoY earnings growth on $26M TTM revenue (-2.9% gross margin, -146.0% operating margin). On trailing 12-month operating scale, AAPG generates $643M in USD-normalized revenue versus $26M for UK. In operating R&D and SG&A reinvestment, AAPG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for UK.

AAPG screens cheaper on headline valuation multiples. AAPG trades at 8.4x Forward P/E, 8.4x Trailing P/E, N/M PEG, and 1.8x EV/Revenue (unreported EBITDA margin), whereas UK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (-133.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AAPG (-236.6% ROE) versus UK (-26.1% ROE) capital efficiency.

In options market volatility and institutional positioning, AAPG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.36β · 64% Vol realized risk). By comparison, UK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (7.12β · 83% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.